Editorial Commentary: Increasing Evidence That Certain Antibiotics Should Be Avoided for Shiga Toxin–ProducingEscherichia coliInfections: More Data Needed

A role for fosfomycin treatment in children for prevention of haemolytic–uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection

(2015) Hitoshi Tajiri et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Shiga toxin-converting phages and the emergence of new pathogenic Escherichia coli: a world in motion

(2014) Rosangela Tozzoli et al.   Frontiers in Cellular and Infection Microbiology

Editorial Commentary: Fecal Shedding of Shiga Toxin-Producing Escherichia coli: What Should Be Done to Prevent Secondary Cases?

(2013) R. K. Mody et al.   CLINICAL INFECTIOUS DISEASES

Isolation and genetic characterization of naturally NS-truncated H3N8 equine influenza virus in South Korea

(2013) W. NA et al.   EPIDEMIOLOGY AND INFECTION

Increased Recognition of Non-O157 Shiga Toxin–Producing Escherichia coli Infections in the United States During 2000–2010: Epidemiologic Features and Comparison with E. coli O157 Infections

(2013) L. Hannah Gould et al.   Foodborne Pathogens and Disease

Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea

(2013) H. F. Geerdes-Fenge et al.   INFECTION

Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain

(2012) Martina Bielaszewska et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infections in Pediatric Postdiarrheal Hemolytic Uremic Syndrome

(2012) Rajal K. Mody et al.   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Risk Factors for the Hemolytic Uremic Syndrome in Children Infected With Escherichia coli O157:H7: A Multivariable Analysis

(2012) C. S. Wong et al.   CLINICAL INFECTIOUS DISEASES

Early Volume Expansion During Diarrhea and Relative Nephroprotection During Subsequent Hemolytic Uremic Syndrome

(2011) Christina A. Hickey   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Epidemiology of a large restaurant-associated outbreak of Shiga toxin-producing Escherichia coli O111:NM

(2011) K. K. BRADLEY et al.   EPIDEMIOLOGY AND INFECTION

Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of Hemolytic Uremic Syndrome, Minnesota

(2011) Kirk E. Smith et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Different Classes of Antibiotics Differentially Influence Shiga Toxin Production

(2010) C. M. McGannon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak

(2010) Emily W. Piercefield et al.   ARCHIVES OF INTERNAL MEDICINE

Effects of Ampicillin, Gentamicin, and Cefotaxime on the Release of Shiga Toxins from Shiga Toxin–Producing Escherichia coli Isolated During a Diarrhea Episode in Faisalabad, Pakistan

(2009) Mashkoor Mohsin et al.   Foodborne Pathogens and Disease

Gnotobiotic Piglet Infection Model for Evaluating the Safe Use of Antibiotics againstEscherichia coliO157:H7 Infection

(2009) Quanshun Zhang et al.   JOURNAL OF INFECTIOUS DISEASES

Subtype-Specific Suppression of Shiga Toxin 2 Released from Escherichia coli upon Exposure to Protein Synthesis Inhibitors

(2008) M. G. Pedersen et al.   JOURNAL OF CLINICAL MICROBIOLOGY